Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.

100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.

pabolizumab

nafulizumab

wang jia lei, doctor

wang jia lei, DOCTOR

To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

Study on the Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer by Detection of Plasma Exosomes

detect the difference of PD-L1 expression profiles of exosomes in NSCLC patients before and after immunotherapy

detect the difference of miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy

Fudan University

Principal Investigator

Symptoms and General Pathology

Rare Diseases

Lung Diseases, Obstructive

Pulmonary Disease, Chronic Obstructive

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

All Drugs and Chemicals

Mitogens

Control group of healthy subjects : simple blood analysis of EPCs

COPD: one initial blood sample and simple clinical follow-up

NSCLC: one initial blood sample and usual clinical follow-up

Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures

Boris MELLONI, Professor

Bone-marrow-derived progenitor cells (EPCS) play an important role in neovascularization and tumor growth. In lung cancer, angiogenesis is an important event in mechanisms of tumor proliferation and metastasis. Recent evidences suggest that EPCS can be recruited and differentiate in mature endothelial cells to form new blood vessels. The role of EPCs in NSCLC is unclear. In contrast, angiogenic drugs are proposed combined to systemic chemotherapy in NSCLC. The aim of this study is to identify EPCs in peripheral blood from patients with NSCLC, by comparison to Chronic Pulmonary Obstructive Disease (COPD), an inflammatory disease.

The aim of this study is to study blood circulating levels bone-marrow-derived progenitor cells (EPCS).

In a first phase, EPCs will be detected in healthy non-smokers volunteers to validate flow cytometry method (n=25). In addition, EPC will e characterized by primary cultures to analyze EPC-specific markers.

In a second phase, EPCs will detect in peripheral blood from 50 patients with Chronic Obstructive Pulmonary Disease (COPD) and 50 patients with non-small cell lung cancers (NSCLC). Primary cultures will be made to confirm EPCS isolation.

Methods: EPCs will be numerated by flow cytometry using CD133, CD146, CD34, CD45 and VEGFR2 antibodies. Primary cultures will be used to identify EPCs at 5-days culture by the same markers. In addition, for BPCO et NSCLC patients, Vascular endothelial cell growth factor (VEGF) concentration will be measured in peripheral sera by ELISA commercial test.

Overall survival will be analyzed for NSCLC in function of initial EPCs concentration. Correlation will be studied between initial VEGF serum concentration and EPCs level.

This study focus on the possibility that EPC determination in peripheral blood could be used as a surrogate marker of standard or antiangiogenic treatment in NSCLC.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer	NCT04427475	NSCLC Patients	pabolizumab nafulizumab	18 Years -	Fudan University
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer	NCT04427475	NSCLC Patients	pabolizumab nafulizumab	18 Years -	Fudan University
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)	NCT00826683	Non-Small Cell ... Chronic Obstruc...	Enumeration of ...	18 Years -	University Hospital, Limoges

Spots Global Cancer Trial Database for nsclc patients